FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.

By
Kathryn Wighton
April 20, 2026
2 min

Conexiant

At a Glance

Category	Detail
Condition	Preclinical drug safety testing
Key Mechanisms	Use of alternative methods including in vitro systems, computational modeling, human-derived platforms, and AI-based tools to reduce animal testing
Target Population	Drug developers and regulatory stakeholders
Care Setting	Preclinical drug development and regulatory review

Key Highlights

FDA met initial 1-year milestones in its April 2025 roadmap to reduce animal testing in preclinical safety studies.
New approach methodologies include in vitro systems, computational toxicology, human-derived platforms, and AI-based tools.
Draft guidances issued to reduce nonhuman primate testing and transition from horseshoe crab–derived endotoxin testing.

Guideline-Based Recommendations

Diagnosis

Recognize limitations of animal models due to poor predictive value for human safety and efficacy.

Management

Implement alternative testing methods when they demonstrate equivalent or improved predictive performance compared to animal models.
Apply weight-of-evidence approaches integrating nonanimal data sources across multiple safety endpoints.

Monitoring & Follow-up

Use FDA’s searchable database to identify where alternative methods are acceptable in regulatory submissions.
Collaborate with international regulators and NIH to evaluate emerging drug development tools.

Risks

Potential safety or efficacy concerns may not be detected if relying solely on animal models due to their limited predictive value.

Patient & Prescribing Data

Not applicable (focus on preclinical drug development)

Reduction in animal testing may lower drug development costs and accelerate availability of safer drugs for patients.

Clinical Best Practices

Adopt alternative testing methodologies validated for predictive accuracy to reduce reliance on animal models.
Incorporate computational and laboratory-based assays in safety evaluations.
Stay informed on FDA guidances and utilize available resources such as AI tools and regulatory databases.